# A Study of LY2523355 in Participants With Breast Cancer

> **NCT01416389** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** LY2523355
- **DRUG:** ixabepilone
- **DRUG:** pegfilgrastim
- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT01416389
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-08
- **Final completion:** 2013-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416389, "A Study of LY2523355 in Participants With Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01416389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*